It didn't take long for Monsanto to unload its controversial milk hormone business. On Wednesday, Eli Lilly announced that it would pay Monsanto $300 million for its recombinant Bovine Growth Hormone (also known as Posilac) business.
Two weeks ago, we wrote about the nearly 15-year battle over rBGH and the strong consumer and business rejection of the product. You have to wonder whether Eli Lilly understands what it is getting into. In a Dow Jones story, Jeff Simmons, president of Lilly's Elanco animal-health unit, implied that the criticism of rBGH has come only from "small groups." But we have to agree with Wenonah Hauter at Food and Water Watch, "Eli Lilly is not helping its shareholders by buying a product that the marketplace is already abandoning."
